RAVE DRUG (ECSTASY) AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTI-DEPRESSANTS by Singh, A.N. & Catalan, J.
Indian Journal of Psychiatry, 2000, 42 (2), 195-197 
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ABSTRACT 
3, 4 Methylenedioxymethamphetamine (MDMA) also known as Ecstasy is a common 
recreational drug of abuse and reports of abuse of tricyclic antidepressants are also known. We 
report two cases of misuse of selective serotonin re-uptake inhibitors (SSRIs) antidepressants in 
combination with Ecstasy and their beneficial subjective effects experienced by misusers. We 
hypothesise the probable underlying pharmacological reasons and recommend its use in the treatment 
of neurotoxic effects of MDMA. 
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3, 4 Methylenedioxymethamphetamine 
(MDMA), Ecstasy, a synthetic analogue of 
amphetamine and mescaline, is a -commonly 
used recreational drug of abuse and has recently 
been the focus of tremendous controversy. It has 
received wide publicity in the popular press and 
medical journals (Lancet, 1996) and a wide range 
of psychopathology ranging from panic attacks, 
depression to psychotic depression has been 
reported (McGuire et al.,1994). Concerns about 
the. abuse potential of any centrally active or 
mood altering drugs are not new (Sheppard, 
1970). There have been reports of abuse of 
amitriptyline in combination with methadone 
(Cohen et al ,1978, Cantor,1979) and recently 
dothiepin misuse has also been reported' 
(Dorman et al.,1995) and the patients who 
misuse dothiepin report euphoria and sedation 
with complex visual and auditory hallucinations. 
Experiences are pleasant and seem to occur in 
clouded consciousness. 
Reports from some of our patients suggest 
that selective serotonin re-uptake inhibitor 
antidepressants combined with MDMA is 
becoming popular with people who go to 
metropolitan clubs and-raves. We are told good 
quality MDMA is becoming harder to find and so 
users are resorting to drug combinations to 
enhance its effects, such as MDMA combined 
with ketamine, an anaesthetic agent, and with 
fluoxetine (Singh, 1995). 
Here we report two cases of misuse of 
SSRI antidepressants, fluoxetine and sertraline 
in combination with MDMA. 
Case 1. Mr. A, a 45 year old ex-dancer 
suffering from HIV infection and no past 
psychiatric illness was receiving treatment for a 
mi'd depressive illness and was on fluoxetine 
20 mg daily. Occasionally he used to go to discos 
and he used to take MDMA. He noticed that the 
days he took Ecstasy, within an hour he felt' a 
rush and enough energy to dance for 2 to 3 
hours'. He also felt that by combining fluoxetine 
this effect was prolonged by a further two hours 
and there was an absence of hangover effects 
and the comedown was easier'. 
Case 2 : Mr. B, a 24 year old unemployed 
man suffering from HIV infection with no past 
history of psychiatric illness was prescribed 
sertraline 50 mg daily by a physician apparently 
for mild depressive illness. He had extensive 
experience with Ecstasy before using it in 
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combination with sertraline. Typically he would 
ingest 50 mg of sertraline before taking Ecstasy 
and his subjective experience was almost 
identical to that of the first case. He also 
experienced initially a rush, prolonged effect, 
easier comdown following a high and it stopped 
comedown depression' and absence of 
hangover effects. 
DISCUSSION 
The cerebral cortex in many mammals is 
inervated by two morpholosically distinct classes 
of 5-HT axon terminals, fine and beaded one. 
These two types of axon have different regional 
and laminer distribution and are differentially 
sensitive to neurotoxic effects of certain 
amphetamine derivatives, which includes 
Ecstasy. Administration of Ecstasy to various 
animals has been shown to cause long term 
destruction of serotonergic axons and axon 
terminals in the brain (Green & Goodwin, 1995). 
The fine axons are much more sensitive to 
neurotoxic effects than the beaded axons, and 
the loss of fine axons lasts for months, whereas 
the beaded axons remain uneffected following 
neurotoxic drug treatment (Mamounas et al., 
1991). An individual using Ecstasy utilise doses 
approaching those shown to be neurotoxic in non-
human primats and indeed a 26% decrease in 5-
hydroxy indoleacetic acid in cerebral spinal fluid 
was found it Ecstasy users (Ricaurte et al., 1990). 
Green & Goodwin (1995) stated that Ecstasy can 
cause neurotoxicity to those serotonergic systems 
of the brain in human being, however, this has 
been questioned (Saunders, 1996). There is no 
doubt the misuse of Ecstasy produces 
neuropsychiatry complications (Macguire et 
al.,1994) In addition to effecting serotonergic 
system it has also been observed that Ecstasy 
reduces CSF, HVA (homovallenic acid) 
particularly in women (McCann et al.,1994), a 
finding that is in keeping with the observation 
that at high doses, Ecstasy can damage 
dopaminergic as well as serotonergic neurons 
(Commins et al., 1987) and a recent crosssectional 
association study, suggested evidence for 
specefic serotonergic neurotoxicity of MDMA in 
humans, using serotonin transporters legend [
123l] 
IJ-CIT(SempleetaL, 1999). 
In the laboratory, SSRI block MDMA 
induced serotonin release and they also block 
MDMA neurotoxicity and it has also been 
reported that fluoxetine does not block MDMAs 
reinforcing subjective effect (McCann & 
Recaurte,1993). 
The two cases described here also 
suggest that the selective serotonin reuptake 
inhibitors, fluoxetine and sertraline, at doses that 
interact with the serotonin uptake sites in human 
does not block the subjective effects of MDMA 
and also that Ecstasy osycho-active effects may 
be separate from its neurotoxic actions. 
Cytochrome P450 2D6 has been 
implicated at the main enzyme involved in 
Ecstasy metabolism and the SSRIs, fluoxetine 
and sertraline are important inhibitors of this 
enzyme, suggesting that they could increase 
blood levels of Ecstasy and thus enhance its 
effect. What is not known is whether single doses 
of these SSRIs are sufficient to inhibit the 
enzyme. It would be interesting if someone could 
measure the rate of metabolism of Ecstasy, with 
and without single doses of SSRIs. Potential 
functional consequences of Ecstacy induced 
brain 5-HT neurotoxic lesions are not yet clear. 
If true, the health implications of this finding could 
be serious. Evidence is now mounting that 
Ecstasy can cause serotonergic, dopaminergic 
and other abnormality in the neurotransmitter 
system and the effect of such a loss of 
"serotonergic/dopaminergic reserve" in later life 
is difficult to predict but could be clinically 
significant and these neurotransmitter systems 
are thought to be involved in the aetiology of 
various common psychiatric illnesses such as 
depression and schizophrenia. Our patients 
subjective experience suggest that SSRIs may 
be useful in limiting the adverse effects of 
Ecstasy as it appears to be mitigating the 
neurotoxic effects of MDMA. Theoretically 
atypical neuroleptics which blocks 5-HT and 
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dopamine may also oe useful. A larger scale 
controlled study is overdue. 
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